FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366692639> ?p ?o ?g. }

• W4366692639 endingPage "1797" @default.
• W4366692639 startingPage "1786" @default.
• W4366692639 abstract "Observational studies suggest that bariatric-metabolic surgery might greatly improve non-alcoholic steatohepatitis (NASH). However, the efficacy of surgery on NASH has not yet been compared with the effects of lifestyle interventions and medical therapy in a randomised trial.We did a multicentre, open-label, randomised trial at three major hospitals in Rome, Italy. We included participants aged 25-70 years with obesity (BMI 30-55 kg/m2), with or without type 2 diabetes, with histologically confirmed NASH. We randomly assigned (1:1:1) participants to lifestyle modification plus best medical care, Roux-en-Y gastric bypass, or sleeve gastrectomy. The primary endpoint of the study was histological resolution of NASH without worsening of fibrosis at 1-year follow-up. This study is registered at ClinicalTrials.gov, NCT03524365.Between April 15, 2019, and June 21, 2021, we biopsy screened 431 participants; of these, 103 (24%) did not have histological NASH and 40 (9%) declined to participate. We randomly assigned 288 (67%) participants with biopsy-proven NASH to lifestyle modification plus best medical care (n=96 [33%]), Roux-en-Y gastric bypass (n=96 [33%]), or sleeve gastrectomy (n=96 [33%]). In the intention-to-treat analysis, the percentage of participants who met the primary endpoint was significantly higher in the Roux-en-Y gastric bypass group (54 [56%]) and sleeve gastrectomy group (55 [57%]) compared with lifestyle modification (15 [16%]; p<0·0001). The calculated probability of NASH resolution was 3·60 times greater (95% CI 2·19-5·92; p<0·0001) in the Roux-en-Y gastric bypass group and 3·67 times greater (2·23-6·02; p<0·0001) in the sleeve gastrectomy group compared with in the lifestyle modification group. In the per protocol analysis (236 [82%] participants who completed the trial), the primary endpoint was met in 54 (70%) of 77 participants in the Roux-en-Y gastric bypass group and 55 (70%) of 79 participants in the sleeve gastrectomy group, compared with 15 (19%) of 80 in the lifestyle modification group (p<0·0001). No deaths or life-threatening complications were reported in this study. Severe adverse events occurred in ten (6%) participants who had bariatric-metabolic surgery, but these participants did not require re-operations and severe adverse events were resolved with medical or endoscopic management.Bariatric-metabolic surgery is more effective than lifestyle interventions and optimised medical therapy in the treatment of NASH.Fondazione Policlinico Universitario A Gemelli, Policlinico Universitario Umberto I and S Camillo Hospital, Rome, Italy." @default.
• W4366692639 created "2023-04-24" @default.
• W4366692639 creator A5002391359 @default.
• W4366692639 creator A5006906048 @default.
• W4366692639 creator A5014472001 @default.
• W4366692639 creator A5015829737 @default.
• W4366692639 creator A5027319711 @default.
• W4366692639 creator A5032982792 @default.
• W4366692639 creator A5033097733 @default.
• W4366692639 creator A5043890435 @default.
• W4366692639 creator A5045314351 @default.
• W4366692639 creator A5047966874 @default.
• W4366692639 creator A5048614462 @default.
• W4366692639 creator A5049039790 @default.
• W4366692639 creator A5049793416 @default.
• W4366692639 creator A5051236994 @default.
• W4366692639 creator A5053488036 @default.
• W4366692639 creator A5053516659 @default.
• W4366692639 creator A5068167563 @default.
• W4366692639 creator A5068798733 @default.
• W4366692639 creator A5070853807 @default.
• W4366692639 creator A5076391635 @default.
• W4366692639 creator A5077447012 @default.
• W4366692639 creator A5080216527 @default.
• W4366692639 creator A5090279484 @default.
• W4366692639 date "2023-05-01" @default.
• W4366692639 modified "2023-10-06" @default.
• W4366692639 title "Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial" @default.
• W4366692639 cites W1844037985 @default.
• W4366692639 cites W2045256747 @default.
• W4366692639 cites W2067740038 @default.
• W4366692639 cites W2090437352 @default.
• W4366692639 cites W2091106363 @default.
• W4366692639 cites W2104183837 @default.
• W4366692639 cites W2104844585 @default.
• W4366692639 cites W2105725047 @default.
• W4366692639 cites W2112496618 @default.
• W4366692639 cites W2144631980 @default.
• W4366692639 cites W2147872784 @default.
• W4366692639 cites W2470709274 @default.
• W4366692639 cites W2556792033 @default.
• W4366692639 cites W2744982526 @default.
• W4366692639 cites W2782960618 @default.
• W4366692639 cites W2955615964 @default.
• W4366692639 cites W2982524592 @default.
• W4366692639 cites W3003361050 @default.
• W4366692639 cites W3022744185 @default.
• W4366692639 cites W3034346518 @default.
• W4366692639 cites W3102426258 @default.
• W4366692639 cites W3123756952 @default.
• W4366692639 cites W3127371223 @default.
• W4366692639 cites W3155125407 @default.
• W4366692639 cites W3196921676 @default.
• W4366692639 cites W3207086349 @default.
• W4366692639 cites W3210471161 @default.
• W4366692639 cites W3214171772 @default.
• W4366692639 cites W4207027817 @default.
• W4366692639 cites W4281934192 @default.
• W4366692639 cites W4303437732 @default.
• W4366692639 cites W4309348832 @default.
• W4366692639 doi "https://doi.org/10.1016/s0140-6736(23)00634-7" @default.
• W4366692639 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37088093" @default.
• W4366692639 hasPublicationYear "2023" @default.
• W4366692639 type Work @default.
• W4366692639 citedByCount "18" @default.
• W4366692639 countsByYear W43666926392023 @default.
• W4366692639 crossrefType "journal-article" @default.
• W4366692639 hasAuthorship W4366692639A5002391359 @default.
• W4366692639 hasAuthorship W4366692639A5006906048 @default.
• W4366692639 hasAuthorship W4366692639A5014472001 @default.
• W4366692639 hasAuthorship W4366692639A5015829737 @default.
• W4366692639 hasAuthorship W4366692639A5027319711 @default.
• W4366692639 hasAuthorship W4366692639A5032982792 @default.
• W4366692639 hasAuthorship W4366692639A5033097733 @default.
• W4366692639 hasAuthorship W4366692639A5043890435 @default.
• W4366692639 hasAuthorship W4366692639A5045314351 @default.
• W4366692639 hasAuthorship W4366692639A5047966874 @default.
• W4366692639 hasAuthorship W4366692639A5048614462 @default.
• W4366692639 hasAuthorship W4366692639A5049039790 @default.
• W4366692639 hasAuthorship W4366692639A5049793416 @default.
• W4366692639 hasAuthorship W4366692639A5051236994 @default.
• W4366692639 hasAuthorship W4366692639A5053488036 @default.
• W4366692639 hasAuthorship W4366692639A5053516659 @default.
• W4366692639 hasAuthorship W4366692639A5068167563 @default.
• W4366692639 hasAuthorship W4366692639A5068798733 @default.
• W4366692639 hasAuthorship W4366692639A5070853807 @default.
• W4366692639 hasAuthorship W4366692639A5076391635 @default.
• W4366692639 hasAuthorship W4366692639A5077447012 @default.
• W4366692639 hasAuthorship W4366692639A5080216527 @default.
• W4366692639 hasAuthorship W4366692639A5090279484 @default.
• W4366692639 hasBestOaLocation W43666926391 @default.
• W4366692639 hasConcept C126322002 @default.
• W4366692639 hasConcept C141071460 @default.
• W4366692639 hasConcept C168563851 @default.
• W4366692639 hasConcept C203092338 @default.
• W4366692639 hasConcept C2775934546 @default.
• W4366692639 hasConcept C2777766500 @default.
• W4366692639 hasConcept C2778586554 @default.

• next